Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients

A multicenter experience

Joseph K. Salama, Loren K. Mell, David A. Schomas, Robert C. Miller, Kiran Devisetty, Ashesh B. Jani, Arno J. Mundt, John C. Roeske, Stanley L. Liauw, Steven J. Chmura

Research output: Contribution to journalArticle

196 Citations (Scopus)

Abstract

Purpose: To report a multicenter experience treating anal canal cancer patients with concurrent chemotherapy and intensity-modulated radiation therapy (IMRT). Patients and Methods: From October 2000 to June 2006, 53 patients were treated with concurrent chemotherapy and IMRT for anal squamous cell carcinoma at three tertiary-care academic medical centers. Sixty-two percent were T1-2, and 67% were N0; eight patients were HIV positive. Forty-eight patients received fluorouracil (FU)/mitomycin, one received FU/cisplatin, and four received FU alone. All patients underwent computed tomography-based treatment planning with pelvic regions and inguinal nodes receiving a median of 45 Gy. Primary sites and involved nodes were boosted to a median dose of 51.5 Gy. All acute toxicity was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. All late toxicity was scored using Radiation Therapy Oncology Group criteria. Results: Median follow-up was 14.5 months (range, 5.2 to 102.8 months). Acute grade 3+ toxicity included 15.1% GI and 37.7% dermatologic toxicity; all acute grade 4 toxicities were hematologic; and acute grade 4 leukopenia and neutropenia occurred in 30.2% and 34.0% of patients, respectively. Treatment breaks occurred in 41.5% of patients, lasting a median of 4 days. Forty-nine patients (92.5%) had a complete response, one patient had a partial response, and three had stable disease. All HIV-positive patients achieved a complete response. Eighteen-month colostomy-free survival, overall survival, freedom from local failure, and freedom from distant failure were 83.7%, 93.4%, 83.9%, and 92.9%, respectively. Conclusion: Preliminary outcomes suggest that concurrent chemotherapy and IMRT for anal canal cancers is effective and tolerated favorably compared with historical standards.

Original languageEnglish (US)
Pages (from-to)4581-4586
Number of pages6
JournalJournal of Clinical Oncology
Volume25
Issue number29
DOIs
StatePublished - Oct 10 2007

Fingerprint

Anus Neoplasms
Anal Canal
Radiotherapy
Drug Therapy
Fluorouracil
HIV
Radiation Oncology
Colostomy
Survival
Groin
Leukopenia
Mitomycin
Tertiary Healthcare
Neutropenia
Pelvis
Terminology
Cisplatin
Squamous Cell Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Salama, J. K., Mell, L. K., Schomas, D. A., Miller, R. C., Devisetty, K., Jani, A. B., ... Chmura, S. J. (2007). Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: A multicenter experience. Journal of Clinical Oncology, 25(29), 4581-4586. https://doi.org/10.1200/JCO.2007.12.0170

Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients : A multicenter experience. / Salama, Joseph K.; Mell, Loren K.; Schomas, David A.; Miller, Robert C.; Devisetty, Kiran; Jani, Ashesh B.; Mundt, Arno J.; Roeske, John C.; Liauw, Stanley L.; Chmura, Steven J.

In: Journal of Clinical Oncology, Vol. 25, No. 29, 10.10.2007, p. 4581-4586.

Research output: Contribution to journalArticle

Salama, JK, Mell, LK, Schomas, DA, Miller, RC, Devisetty, K, Jani, AB, Mundt, AJ, Roeske, JC, Liauw, SL & Chmura, SJ 2007, 'Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: A multicenter experience', Journal of Clinical Oncology, vol. 25, no. 29, pp. 4581-4586. https://doi.org/10.1200/JCO.2007.12.0170
Salama, Joseph K. ; Mell, Loren K. ; Schomas, David A. ; Miller, Robert C. ; Devisetty, Kiran ; Jani, Ashesh B. ; Mundt, Arno J. ; Roeske, John C. ; Liauw, Stanley L. ; Chmura, Steven J. / Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients : A multicenter experience. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 29. pp. 4581-4586.
@article{7579130542494245abb4a077f6a08c00,
title = "Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: A multicenter experience",
abstract = "Purpose: To report a multicenter experience treating anal canal cancer patients with concurrent chemotherapy and intensity-modulated radiation therapy (IMRT). Patients and Methods: From October 2000 to June 2006, 53 patients were treated with concurrent chemotherapy and IMRT for anal squamous cell carcinoma at three tertiary-care academic medical centers. Sixty-two percent were T1-2, and 67{\%} were N0; eight patients were HIV positive. Forty-eight patients received fluorouracil (FU)/mitomycin, one received FU/cisplatin, and four received FU alone. All patients underwent computed tomography-based treatment planning with pelvic regions and inguinal nodes receiving a median of 45 Gy. Primary sites and involved nodes were boosted to a median dose of 51.5 Gy. All acute toxicity was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. All late toxicity was scored using Radiation Therapy Oncology Group criteria. Results: Median follow-up was 14.5 months (range, 5.2 to 102.8 months). Acute grade 3+ toxicity included 15.1{\%} GI and 37.7{\%} dermatologic toxicity; all acute grade 4 toxicities were hematologic; and acute grade 4 leukopenia and neutropenia occurred in 30.2{\%} and 34.0{\%} of patients, respectively. Treatment breaks occurred in 41.5{\%} of patients, lasting a median of 4 days. Forty-nine patients (92.5{\%}) had a complete response, one patient had a partial response, and three had stable disease. All HIV-positive patients achieved a complete response. Eighteen-month colostomy-free survival, overall survival, freedom from local failure, and freedom from distant failure were 83.7{\%}, 93.4{\%}, 83.9{\%}, and 92.9{\%}, respectively. Conclusion: Preliminary outcomes suggest that concurrent chemotherapy and IMRT for anal canal cancers is effective and tolerated favorably compared with historical standards.",
author = "Salama, {Joseph K.} and Mell, {Loren K.} and Schomas, {David A.} and Miller, {Robert C.} and Kiran Devisetty and Jani, {Ashesh B.} and Mundt, {Arno J.} and Roeske, {John C.} and Liauw, {Stanley L.} and Chmura, {Steven J.}",
year = "2007",
month = "10",
day = "10",
doi = "10.1200/JCO.2007.12.0170",
language = "English (US)",
volume = "25",
pages = "4581--4586",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "29",

}

TY - JOUR

T1 - Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients

T2 - A multicenter experience

AU - Salama, Joseph K.

AU - Mell, Loren K.

AU - Schomas, David A.

AU - Miller, Robert C.

AU - Devisetty, Kiran

AU - Jani, Ashesh B.

AU - Mundt, Arno J.

AU - Roeske, John C.

AU - Liauw, Stanley L.

AU - Chmura, Steven J.

PY - 2007/10/10

Y1 - 2007/10/10

N2 - Purpose: To report a multicenter experience treating anal canal cancer patients with concurrent chemotherapy and intensity-modulated radiation therapy (IMRT). Patients and Methods: From October 2000 to June 2006, 53 patients were treated with concurrent chemotherapy and IMRT for anal squamous cell carcinoma at three tertiary-care academic medical centers. Sixty-two percent were T1-2, and 67% were N0; eight patients were HIV positive. Forty-eight patients received fluorouracil (FU)/mitomycin, one received FU/cisplatin, and four received FU alone. All patients underwent computed tomography-based treatment planning with pelvic regions and inguinal nodes receiving a median of 45 Gy. Primary sites and involved nodes were boosted to a median dose of 51.5 Gy. All acute toxicity was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. All late toxicity was scored using Radiation Therapy Oncology Group criteria. Results: Median follow-up was 14.5 months (range, 5.2 to 102.8 months). Acute grade 3+ toxicity included 15.1% GI and 37.7% dermatologic toxicity; all acute grade 4 toxicities were hematologic; and acute grade 4 leukopenia and neutropenia occurred in 30.2% and 34.0% of patients, respectively. Treatment breaks occurred in 41.5% of patients, lasting a median of 4 days. Forty-nine patients (92.5%) had a complete response, one patient had a partial response, and three had stable disease. All HIV-positive patients achieved a complete response. Eighteen-month colostomy-free survival, overall survival, freedom from local failure, and freedom from distant failure were 83.7%, 93.4%, 83.9%, and 92.9%, respectively. Conclusion: Preliminary outcomes suggest that concurrent chemotherapy and IMRT for anal canal cancers is effective and tolerated favorably compared with historical standards.

AB - Purpose: To report a multicenter experience treating anal canal cancer patients with concurrent chemotherapy and intensity-modulated radiation therapy (IMRT). Patients and Methods: From October 2000 to June 2006, 53 patients were treated with concurrent chemotherapy and IMRT for anal squamous cell carcinoma at three tertiary-care academic medical centers. Sixty-two percent were T1-2, and 67% were N0; eight patients were HIV positive. Forty-eight patients received fluorouracil (FU)/mitomycin, one received FU/cisplatin, and four received FU alone. All patients underwent computed tomography-based treatment planning with pelvic regions and inguinal nodes receiving a median of 45 Gy. Primary sites and involved nodes were boosted to a median dose of 51.5 Gy. All acute toxicity was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. All late toxicity was scored using Radiation Therapy Oncology Group criteria. Results: Median follow-up was 14.5 months (range, 5.2 to 102.8 months). Acute grade 3+ toxicity included 15.1% GI and 37.7% dermatologic toxicity; all acute grade 4 toxicities were hematologic; and acute grade 4 leukopenia and neutropenia occurred in 30.2% and 34.0% of patients, respectively. Treatment breaks occurred in 41.5% of patients, lasting a median of 4 days. Forty-nine patients (92.5%) had a complete response, one patient had a partial response, and three had stable disease. All HIV-positive patients achieved a complete response. Eighteen-month colostomy-free survival, overall survival, freedom from local failure, and freedom from distant failure were 83.7%, 93.4%, 83.9%, and 92.9%, respectively. Conclusion: Preliminary outcomes suggest that concurrent chemotherapy and IMRT for anal canal cancers is effective and tolerated favorably compared with historical standards.

UR - http://www.scopus.com/inward/record.url?scp=35648948442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35648948442&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.12.0170

DO - 10.1200/JCO.2007.12.0170

M3 - Article

VL - 25

SP - 4581

EP - 4586

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 29

ER -